Bernstock, Joshua D. http://orcid.org/0000-0002-7814-3867
Vicario, Nunzio http://orcid.org/0000-0001-5934-3962
Li, Rong
Nan, Li
Totsch, Stacie K.
Schlappi, Charles
Gessler, Florian
Han, Xiaosi
Parenti, Rosalba
Beierle, Elizabeth A.
Whitley, Richard J.
Aban, Inmaculada
Gillespie, G. Yancey
Markert, James M.
Friedman, Gregory K.
Article History
Received: 18 January 2019
Accepted: 12 March 2019
First Online: 28 March 2019
Compliance with ethical standards
:
: JMM and GYG are founders of and own stock and stock options (<8% interest) in Aettis, Inc., a biotech company that has licensed M032 HSV from The Board of Trustees of the University of Alabama for the University of Alabama at Birmingham and is developing other oHSVs that are not the subject of this current investigation. GYG currently serves as one of five unpaid members of the Board of Directors for Aettis, Inc. GYG is a founder of and owns stock and stock options (<10%) in Maji Therapeutics, which is developing other HSVs that are not the subject of the current investigation. JMM and GYG were also founders of and owned stock and stock options (<8%) in Catherex Inc., a biotechnology company that had licensed additional intellectual property related to oHSV. Catherex, Inc. was sold to Amgen, Inc. on 18 December 2015, and they no longer participate in any decision making or have any control of any aspect of Catherex or Amgen, although they did receive proceeds from the sale of the company. GYG has served as a paid advisor to the Program Project at the Ohio State University that seeks to find improved methods for application of distinct oHSV to treat localized and metastatic cancers. This is generally, but not specifically, related to the subject matter of this investigation. JDB has equity (≤5°%) in both CITC Ltd and Avidea Technologies.